Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Justin Smith has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Quality of Life After Postprostatectomy Radiotherapy: A TROG 08.03 RAVES Randomized Controlled Trial Substudy

    by Justin Smith, Gill M. Duchesne, Andrew Kneebone, Maria Pearse, Carol Fraser-Browne, Lucy Leigh, Margot Lehman, Sandra Turner, Colin I. Tang, Mark Sidhom, et al.

  • Sensorineural hearing outcomes in HPV-positive oropharyngeal cancer: a secondary analysis of the TROG 12.01 randomized trial (SHOUT)

    by Laurelie R. Wishart, Julianne O’SHea, Danny Rischin, June Corry, Benjamin J Dixon, Stephen O’LEary, Wayne J. Wilson, Syeda Farah Zahir, Dominic Hanson, Justin Smith, et al.

  • Open Access

    Healthcare costs in patients with head and neck cancer

    by Justin Smith, Madhavi Chilkuri, Daniel Lindsay, Katharina M. D. Merollini

    Purpose: The aim of this study was to quantify the healthcare costs of patients with head and neck cancer (HNC) in Australia and investigate factors associated with increased costs. Methods: A sub-study was performed using linked patient data from ‘Lifetime Costs of Surviving Cancer – A Queensland Study (COS-Q).’ Queensland residents diagnosed with a first primary mucosal head and neck squamous cell carcinoma (HNSCC) between 1997 and 2015 and who incurred costs from 2013 to 2016 were included. Healthcare costs were reported as a total mean cost per patient per year and included emergency department (ED) costs, hospital admission costs, cost for medical and allied health services and pharmaceutical costs. Results: There were 4929 patients with HNSCC included in the study. The total mean annual cost was $21,646 per patient with the highest costs in the first-year post treatment. Regional ($23,312) and rural ($33,627) patients experienced higher healthcare costs than those from major cities ($20,300, p < 0.001). Factors strongly associated with an increased overall healthcare cost included living in a remote location (RR 1.51, p < 0.001), having a nasopharynx (RR 1.41, p = 0.027) or hypopharynx (RR 1.60, p < 0.001) cancer or never married (RR 1.34, p < 0.001). There were 644 patients (13%) who developed a second primary malignancy and this sub-group experienced higher overall costs ($46,453 vs $24,966, p < 0.001). Conclusion: Healthcare costs for patients with HNC are significant. Further research is needed to investigate ways to reduce healthcare utilisation and provide additional support in this cohort.

  • Radiotherapy for extramedullary haematopoiesis of the mandibular mucosa secondary to myelofibrosis

    by Justin Smith, Claire Weatherburn, Serena Kosciejew, Caroline Cooper, Yoo Young Lee

    Extramedullary haematopoiesis (EMH) is a clinical manifestation of myelofibrosis (MF), which can lead to significant localised symptoms. A patient in her 70s with a history of MF presented with a symptomatic bleeding site of EMH in the right mandibular mucosa following dental removal, which limited her oral intake to a liquid diet. The EMH site was treated with radiotherapy (RT), administering 10 Gy in five fractions and another 10 Gy in five fractions 3 months later, resulting in a complete response and resolution of symptoms. This case highlights that RT is an effective and well-tolerated treatment for patients with symptomatic sites of EMH.

  • Open Access

    Cardioprotective medications and the incidence of cardiovascular events in patients treated with radiotherapy: a systematic review and meta-analysis

    by Vishwa Pakeerathan, Ravi Marwah, Abdul Rahman Mohammed, Justin Smith

    Purpose: The purpose of this systematic review and meta-analysis is to explore the utilization of cardioprotective medications in patients treated with RT and assess their impact on cardiovascular and cerebrovascular events. Materials/methods: A literature search of PubMed, Embase and Scopus was performed in March 2025. Studies of adult patients treated with RT to the head and neck or thoracic regions which investigated the effects of cardioprotective medications (defined as anti-hypertensives, lipid-lowering therapies or anti-thrombotic medications) on the incidence of cardiovascular or cerebrovascular events were eligible for inclusion. Studies that reported the proportion of patients treated with RT who were utilizing cardioprotective medications as recommended by CVD guidelines were also included. Meta-analysis was performed using R with a random effects model. Results: There were 10 retrospective studies which were eligible for inclusion. Five of the ten studies included patients with head and neck cancer only, whilst two studies included patients with lung cancer and one study included patients with breast cancer alone. Meta-analysis of three studies suggested that patients treated with RT who received statin therapy had a reduced risk of cerebrovascular events (stroke or transient ischemic attack), with a relative risk of 0.74 (95% CI 0.60-0.90). There was no difference in major adverse cardiac events (MACE) for patients treated with RT to the head and neck or thoracic regions who received statin therapy compared to those who did not (relative risk 0.99, 95% CI 0.67 to 1.46, n = 5 studies). A meta-analysis of four studies suggested that 59% (95% CI 35% to 80%) of patients treated with RT not on statin therapy had indications for commencement of these medications. Conclusion: Current evidence exploring the impact of cardioprotective medications on CVD risk in patients treated with RT is heterogenous and limited to retrospective non-randomized studies. A considerable proportion of patients undergoing RT are not being prescribed cardioprotective medications as suggested by existing CVD guidelines.


  • Delays to Post‐Operative Radiotherapy in Patients With Head and Neck Squamous Cell Carcinoma: A Mixed‐Methods Analysis of Health Worker Perspectives

    by Ravi Marwah, Justin Smith, Daniel Goonetilleke, Liela Murison, Madhavi Chilkuri

    Introduction: Post‐operative radiation therapy (PORT) delays are associated with reduced survival and higher recurrence rates in patients with head and neck squamous cell carcinoma (HNSCC). This study explores health worker perspectives on barriers and solutions to timely PORT in an Australian regional centre with a large Aboriginal and Torres Strait Islander population. Methods: This paper incorporated an explanatory sequential mixed methods design. Head and neck multidisciplinary team (HNMDT) members involved in the care of patients with HNSCC at a regional tertiary centre were invited to participate. Participants completed an online survey and underwent semi‐structured focus groups/interviews. Results: Nineteen healthcare workers participated in the surveys. The three factors most attributed to PORT delays were rurality, surgery at an external facility and Indigenous status. Ten healthcare workers subsequently participated in focus groups/interviews. Three themes regarding solutions to PORT delays were identified: addressing care fragmentation, improving care coordination and ensuring cultural safety in Aboriginal and Torres Strait Islander care. Strategies proposed to address care fragmentation included streamlining referral pathways, utilising electronic reminders for clinicians and coordinators to prompt follow‐up, and increasing local service provision. Solutions suggested to improve care coordination included flagging patients early for follow‐up, timely organisation of transport and accommodation, and employing head and neck‐specific cancer care coordinators. Strategies proposed to ensure cultural safety included instituting cultural immersion programmes, promoting earlier Indigenous Liaison Officer engagement, supporting family involvement, and developing culturally appropriate patient resources. Conclusion: This study highlights barriers and solutions to timely PORT in an Australian regional centre with a large Aboriginal and Torres Strait Islander population. Strategies aimed at the patient and systems level and formed in partnership with Indigenous peoples must be instituted to address delays.

  • Red Journal Reviews: Typology, Methodology, and Standards

    by Justin Smith, Daniel R. Dickstein, Alekhya Mitta, David Sher, Sue S. Yom, Lachlan McDowell

  • Open Access

    Adapting to change: exploring perceptions and demands of the coronavirus (COVID-19) workforce changes – an Australian multi-institutional radiation oncology survey

    by Honor Magon, Justin Smith, Jacqueline Besson, Eric Hau, Suzanne Taylor, Jeremy Ruben, Diana Jones, Kira Mabb, Jamie Feldman, Leily Gholam Rezaei, et al.

    Objective: To evaluate the perceptions of the coronavirus disease 2019 (COVID-19) initiated workplace strategies implemented in radiation oncology departments across Australia. Methods: A multidisciplinary team from Princess Alexandra Hospital developed a survey to address the impact of the pandemic strategies on areas such as patient care, staff education, well-being, flexible working arrangements, and research. The survey was conducted from November 2020 to April 2021. Results: Out of 210 respondents from seven institutions, 45% reported burnout and 57% experienced work work-related stress. A significant majority of respondents were in favour of continued remote work (86%, 131/153). Radiation oncologists identified administrative or non-clinical work (92%, 34/37), telehealth clinics (32%, 12/37), or radiation therapy planning (22%, 8/37) as suitable for remote work. Additionally, 54% (21/39) of the radiation oncologists plan to use telehealth more frequently, with 67% (26/39) feeling more confident with the technology. The majority (81%, 171/210) of participants favoured continuation of hybrid in-person and virtual meetings. Virtual solutions were adopted for quality assurance activities (72%, 118/165) and 52% (60/116) indicated preference for ongoing utility of virtual platforms. However, 38% (79/210) of the respondents expressed concerns about the negative impact on junior staff training. Conclusion: These findings reveal a strong inclination towards technological advancements and remote work arrangements to enable flexible working conditions. Our study suggests the need for ongoing reforms, focusing on improving clinical service delivery efficiencies and enhancing job satisfaction among clinicians.


  • Open Access

    Financial Toxicity and Out-of-Pocket Costs for Patients with Head and Neck Cancer

    by Justin Smith, Justin Yu, Louisa G. Gordon, Madhavi Chilkuri

    Aim: To quantify financial toxicity and out-of-pocket costs for patients with HNC in Australia and explore their relationship with health-related quality of life (HRQoL). Methods: A cross-sectional survey was administered to patients with HNC 1–3 years after radiotherapy at a regional hospital in Australia. The survey included questions on sociodemographics, out-of-pocket expenses, HRQoL, and the Financial Index of Toxicity (FIT) tool. The relationship between high financial toxicity scores (top quartile) and HRQoL was explored. Results: Of the 57 participants included in the study, 41 (72%) reported out-of-pocket expenses at a median of AUD 1796 (IQR AUD 2700) and a maximum of AUD 25,050. The median FIT score was 13.9 (IQR 19.5) and patients with high financial toxicity (n = 14) reported poorer HRQoL (76.5 vs. 114.5, p < 0.001). Patients who were not married had higher FIT scores (23.1 vs. 11.1, p = 0.01), as did those with lower education (19.3 vs. 11.1, p = 0.06). Participants with private health insurance had lower financial toxicity scores (8.3 vs. 17.6, p = 0.01). Medications (41%, median AUD 400), dietary supplements (41%, median AUD 600), travel (36%, median AUD 525), and dental (29%, AUD 388) were the most common out-of-pocket expenses. Participants living in rural locations (≥100 km from the hospital) had higher out-of-pocket expenses (AUD 2655 vs. AUD 730, p = 0.01). Conclusion: Financial toxicity is associated with poorer HRQoL for many patients with HNC following treatment. Further research is needed to investigate interventions aimed at reducing financial toxicity and how these can best be incorporated into routine clinical care.